ANEB · Anebulo Pharmaceuticals, Inc.
Market Cap
$13.46M
Shares
40.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.43
Open$0.35
Day$0.35–0.49
52W close$0.36–3.33
Avg vol 30d108K
Short int6K · 0.0% float · 6.2d
Short vol100%
DataMay 2021–Mar 2026
Filing10-Q · Feb 12
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed Feb 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−76%
below
Price vs 50-day avg
−54%
below
RSI (14)
29
oversold
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−59%
trailing
6-month return
−80%
trailing
YTD return
−57%
this year
Relative strength
−86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.01% of float · ▬ 0.0% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 4-yr range
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
133%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
20.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−76%
Bearish
Price vs 50-day avg
−54%
Bearish
RSI (14)
29
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.01% of float · ▬ 0.0% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 4-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 2%
Range high $3
vs 200-day avg -76%
vs 50-day avg -54%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANEB
this stock
Anebulo Pharmaceuticals, Inc.
|
$13.46M | -57.0% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
19
- % held
- 54.5%
- Net QoQ
- -11.0K sh
- Top holder
- 22NW, LP
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANEB | -0.2% | -58.7% | -80.3% | +20.6% | -57.0% |
| SPY | +0.6% | -0.8% | +5.8% | +0.1% | +0.7% |
| vs SPY | -0.8% | -57.9% | -86.1% | +20.5% | -57.7% |